In NCSLC, overexpression of AURKA and AURKB has been associated with poor prognosis due to reduced overall survival [16,17,18,19,20,21,22,23,24] and both kinases have been found to either potentiate or repress chemo- and/or radiotherapy in lung cancer [1,25,26,27]. Here, AURKB is linked to lung carcinoma.